Gene therapy for the hemophilias

Current Opinion in Pediatrics

Volumn 14, Issue 1, 2002, Pages 12-16

  Walsh, Christopher E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADENOVIRUS; BLEEDING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; CELL TRANSPLANTATION; CLINICAL TRIAL; DNA VECTOR; FIBROBLAST; GENE THERAPY; GENE TRANSFER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM;

ANTIBODY FORMATION; CLINICAL TRIALS; FACTOR IX; FACTOR VIII; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HUMANS;

EID: 0036176784     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200202000-00003     Document Type: Review

References (63)

1. Advances toward gene therapy for hemophilia at the millennium
2. Structure, biology and genetics of factor VIII
3. Hemophilia treatment: Gene therapy, factor VIII antibodies and immune tolerance: Hopes and concerns
4. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A
5. Clinical aspects and therapy for hemophilia B
6. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
7. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs
8. Sustained expression of human factor VIII in mice using a parvovirus-based vector
9. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice
10. Stage I clinical trial of gene therapy for hemophilia B
11. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
12. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
13. The basic science of gene therapy
14. In vivo gene delivery by lentiviral vectors
15. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin
16. HIV-1 genome nuclear import is mediated by a central DNA flap
17. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SOID mice by HIV vectors
18. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice
19. Complete short-term correction of canine hemophilia A by in vivo gene therapy
20. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
21. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A
22. AAV vectors: Is clinical success on the horizon?
23. Immune responses to adenovirus and adeno-associated virus in humans
24. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
25. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
26. Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes
27. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors
28. Gene therapy vectors based on adeno-associated virus type 1
29. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
30. Adeno-associated viral vectors
31. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
32. Sustained and complete phenotype cor-rection of hemophilia b mice following intramuscular injection of AAV1 sero-type vectors
33. Naked DNA delivered intraportally expresses efficiently in hepatocytes
34. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
35. Use of recombinant factor VIIa in hereditary bleeding disorders
36. Induction of tolerance to human factor VIII in mice
37. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency
38. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
39. Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B
40. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
41. Novel gene therapy approach to hemophilia: Use of stably transfected blood outgrowth endothelial cells (BOEC)
42. Expression of human factor IX in rat capillary endothelial cells: Toward somatic gene therapy for hemophilia B
43. Expression of human factor IX in mice after injection of genetically modified myoblasts
44. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine
45. In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery
46. Towards gene therapy for hemophilia B
47. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs
48. Bone marrow stromal cells as targets for gene therapy of hemophilia A
49. Toward gene therapy in haemophilia A: Retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells
50. Towards gene therapy for haemophilia B using primary human keratinocytes
51. Gut epithelial cells as targets for gene therapy of hemophilia
52. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotio cavity: A model for the prenatal treatment of haemophilia B
53. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero
54. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A
55. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
56. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
57. Gene therapy for the treatment of hemophilia b using pinc-formulated plasmid delivered to muscle with electropotation
58. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro
59. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system
60. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice
61. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: Modelling gene therapy for haemophilia
62. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients
63. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector